INVASIVE DUCTAL CARCINOMA OF BREAST IN A 53 Y OLD MALE: A RARE CASE REPORT WITH LITERATURE REVIEW

PRAGNYA PARAMITA MISHRA; PREMANAND PANDA

doi:10.22159/ijcpr.2025v17i2.6080

Authors

PRAGNYA PARAMITA MISHRA Department of Pathology, Hi-Tech MCH, Rourkela-769004, Odisha, India
PREMANAND PANDA Department of Radiology, JP hospital and Research Centre, Rourkela, Odisha, India

DOI:

https://doi.org/10.22159/ijcpr.2025v17i2.6080

Keywords:

Male breast cancer, Diagnosis, Genetics, Neurofibroma, Mutation

Abstract

Male breast cancer is infrequently seen, representing less than 1% of all breast cancer cases and less than 1.5% of all cancers in men. Because of a lack of awareness, it leads to late presentation and diagnosis. Because of its rarity, very little is known about its risk factors, including hormonal and genetic anomalies. According to certain research, the distribution of tumor subtypes in male breast cancer differs from that in female breast cancer, which could indicate significant biological and prognostic variations. Larger studies need to be conducted stating which genetic abnormalities contribute to breast cancer in men and in determining which markers serve as crucial prognostic indicators. Our case is a 53-year-old male who presented with advanced-stage breast cancer with axillary lymphadenopathy in a setting of multiple neurofibromas.

Downloads

Download data is not yet available.

References

Rudlowski C. Male breast cancer. Breast Care (Basel). 2008;3(3):183-9. doi: 10.1159/000136825, PMID 20824037.

Crichlow RW, Galt SW. Male breast cancer. Surg Clin North Am. 1990;70(5):1165-77. doi: 10.1016/s0039-6109(16)45237-0, PMID 2218826.

Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137(8):678-87. doi: 10.7326/0003-4819-137-8-200210150-00013.

Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol. 2013;717(1-3):71-83. doi: 10.1016/j.ejphar.2013.03.037, PMID 23545364.

Couch FJ, Farid LM, DE Shano ML, Tavtigian SV, Calzone K, Campeau L. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996 May;13(1):123-5. doi: 10.1038/ng0596-123, PMID 8673091.

Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365-72. doi: 10.1093/jnci/94.18.1365, PMID 12237282.

Meijers Heijboer H, Van Den Ouweland A, Klijn J, Wasielewski M, DE Snoo A, Oldenburg R. Low penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002 May;31(1):55-9. doi: 10.1038/ng879, PMID 11967536.

Kornegoor R, Verschuur Maes AH, Buerger H, Hogenes MC, DE Bruin PC, Oudejans JJ. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol. 2012 Mar;25(3):398-404. doi: 10.1038/modpathol.2011.174, PMID 22056953.

Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114-22. doi: 10.1200/JCO.2009.25.5729, PMID 20308661.

Brinton LA, Carreon JD, Gierach GL, MC Glynn KA, Gridley G. Etiologic factors for male breast cancer in the U.S. Veterans affairs medical care system database. Breast Cancer Res Treat. 2010;119(1):185-92. doi: 10.1007/s10549-009-0379-0, PMID 19330525.